Month: May 2020
-
Grant from Independent Research Fund DK
Hormonal sensitivity and brain function: Do oral contraceptives distort serotonergic brain architecture and does discontinuation restore it? FORSKNINGSPROJEKT 1 SUNDHED OG SYGDOM 2020 link MODTAGER Vibe Gedsø Frøkjær RIGSHOSPITALET BEVILGET BELØB 2.051.690 kr Women who use oral contraceptives face an increased risk of developing depressive episodes. We do not know why. Recent cross-sectional findings from our…
-
Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol
Front Pharmacol. 2020 Apr 30;11:591. doi: 10.3389/fphar.2020.00591. eCollection 2020. ABSTRACT BACKGROUND: All current approved antipsychotic drugs against schizophrenia spectrum disorders share affinity for the dopamine receptor (D2R). However, up to one-third of these patients respond insufficiently, and in some cases, side-effects outweigh symptom reduction. Previous data have suggested that a subgroup of antipsychotic-naïve patients will…
-
Pharmacological sex hormone manipulation as a risk model for depression
J Neurosci Res. 2020 Jul;98(7):1283-1292. doi: 10.1002/jnr.24632. Epub 2020 May 12. ABSTRACT Sex hormone transition may trigger severe depressive episodes in some women. In order to map mechanisms related to such phenomena we developed a pharmacological preclinical human model using sex hormone manipulation with gonadotropin releasing hormone agonist (GnRHa) in a placebo-controlled design. Here the…
-
Pharmacological sex hormone manipulation as a risk model for depression.
Related Articles Pharmacological sex hormone manipulation as a risk model for depression. J Neurosci Res. 2020 May 12;: Authors: Frokjaer VG Abstract Sex hormone transition may trigger severe depressive episodes in some women. In order to map mechanisms related to such phenomena we developed a pharmacological preclinical human model using sex hormone manipulation with gonadotropin…
-
Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol.
Related Articles Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. Front Pharmacol. 2020;11:591 Authors: Baltzersen OB, Meltzer HY, Frokjaer VG, Raghava JM, Baandrup L, Fagerlund B, Larsson HBW, Fibiger HC, Glenthøj BY, Knudsen GM, Ebdrup BH Abstract Background: All current approved antipsychotic drugs against schizophrenia…